HepaTx

San Francisco, US · Founded 2015 · 4 employees · 2 known investors

HepaTx develops stem cell-based hepatocyte therapies for liver disease treatment as an alternative to organ transplantation. The company targets niche liver disease indications including alpha-1 antitrypsin deficiency, phenylketonuria, and non-alcoholic steatohepatitis.